Deals In Depth: October 2011
October’s dealmaking highlights: Biogen received exclusive global rights to Portola’s autoimmune and anti-inflammatory Syk inhibitors in an alliance worth $554 million. Investment firms took public CRO Pharmaceutical Product Development private for $33.25 per share, or a total of $3.9 billion, including debt. Regeneron’s $391 million notes sale propelled the debt category to claim almost half of the $826 million biopharma financing figure. Meantime device companies raised $206 million, mainly from Zeltiq’s $93 million IPO.
You may also be interested in...
Medical device manufacturers are operating in what may be the industry’s most challenging business and regulatory environment in recent history, attorneys Bill McConagha and Pamela Amaechi argue in this guest article.
Biolife4D CEO dropped president title and Cryo-Cell International co-chief executive officer dropped director title to open spots for new executives; Essex Bio-Technology deputy managing director was promoted to executive director; and more.
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.